Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
TRANSGENIC, Jul-Sep (2Q) Ordinary Profit Turns to Profit
2342 TRANSGENIC GROUP INC. 【J-GAAP】
Earnings ReportTRANSGENIC GROUP INC. <2342> [TSE Growth] announced its financial results after the market closed on November 12th (15:45). The consolidated ordinary profit/loss for the cumulative second quarter of the fiscal year ending March 2026 (April to September) turned into a profit of 83 million yen (compared to a loss of 156 million yen in the same period last year). Progress toward the full-year plan of 90 million yen was 92.2%, also surpassing the five-year average of 69.4%.
Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit/loss for the October to March period (second half) is expected to turn into a profit of 7 million yen (compared to a loss of 163 million yen in the same period last year).
In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit/loss turned to a profit of 22 million yen (compared to a loss of 39 million yen in the same period last year). The operating profit/loss margin improved from -0.2% in the same period last year to 0.9%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2023 | 6,377 | 88 | 94 | 48 | 2.9 | 87.0 | Nov 10, 2023 | J-GAAP |
| Apr - Sep, 2024 | 6,311 | -110 | -156 | -182 | -11.0 | ー | Nov 12, 2024 | J-GAAP |
| Apr - Sep, 2025 | 6,224 | 71 | 83 | 29 | 1.8 | 92.2 | Nov 12, 2025 | J-GAAP |
| YoY | -1.4% | - | - | - | - |
First Half Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Sep, 2025 Guidance | ー | ー | ー | ー | - | 0 | Jun 16, 2025 | J-GAAP |
| Apr - Sep, 2025 Results | 6,224 | 71 | 83 | 29 | 1.8 | 0 | Nov 12, 2025 | J-GAAP |
| Revision Rate | - | - | - | - | - |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 6,694 | -149 | -163 | -907 | -54.6 | 0 | Jun 16, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 7,276 | 79 | 7 | 11 | 0.7 | 0 | Nov 12, 2025 | J-GAAP |
| YoY | +8.7% | - | - | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 13,083 | 89 | 108 | 4 | 0.2 | 3 | May 10, 2024 | J-GAAP |
| Mar, 2025 | 13,005 | -259 | -319 | -1,089 | -65.5 | 0 | Jun 16, 2025 | J-GAAP |
| Mar, 2026 Guidance | 13,500 | 150 | 90 | 40 | 2.4 | 0 | Jun 16, 2025 | J-GAAP |
| YoY | +3.8% | - | - | - | - |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Sep, 2024 | 3,429 | -7 | -39 | -83 | -5.0 | -0.2 | Nov 12, 2024 | J-GAAP |
| Oct - Dec, 2024 | 3,496 | -16 | -6 | -109 | -6.6 | -0.5 | Feb 14, 2025 | J-GAAP |
| Jan - Mar, 2025 | 3,198 | -133 | -157 | -798 | -48.0 | -4.2 | Jun 16, 2025 | J-GAAP |
| Apr - Jun, 2025 | 3,197 | 45 | 61 | 26 | 1.6 | 1.4 | Aug 12, 2025 | J-GAAP |
| Jul - Sep, 2025 | 3,027 | 26 | 22 | 3 | 0.2 | 0.9 | Nov 12, 2025 | J-GAAP |
| YoY | -11.7% | - | - | - | - |
Related Articles
StemCell Institute, First Half Ordinary Profit Decreases by 48%, Jul-Sep Ordinary Profit Decreases by 51%
MAMEZO DIGITAL, 17% Increase in Undisclosed Ordinary Profit, Update Record High for Fifth Consecutive Term
SUGITA ACE, First Half Ordinary Profit Turns to Profit, Postponed Dividend for This Fiscal Year
Systems Engineering Consultants, Jul-Sep (2Q) Ordinary Profit Increases by 32%
DAISHIN CHEMICAL, Jul-Sep (2Q) Ordinary Profit Increases by 77%
NAGANO KEIKI , First Half Ordinary Profit Decreases by 21%, Current Fiscal Year Dividend Revised Upward by 2 Yen
NIHON FALCOM, 5% Decrease in Ordinary Profit for The Current Fiscal Year
Petgo, First Half Ordinary Profit Turns to Loss, Jul-Sep Ordinary Profit Turns to Loss
Kringle Pharma, The Current Fiscal Year's Net Income to Widen
JAPAN MATERIAL, Jul-Sep (2Q) Ordinary Profit Increases by 53%